How Common Is Hypercortisolism in Patients With Type 2 Diabetes? Risk Factors, Epidemiology, and Making a Diagnosis Using a Dexamethasone Suppression Test Authors: Jenine Yager Stone, Timothy S. Bailey Published: 2026 ABSTRACT ABSTRACTImportanceHypercortisolism is an underdiagnosed contributor to metabolic dysfunction in people with Type 2 diabetes (T2D). Although overt Cushing syndrome is rare, milder forms of cortisol excess, commonly termed mild autonomous cortisol secretion (MACS), appear substantially more common in selected high‐risk populations.ObservationsChronic cortisol excess contributes directly to insulin resistance, hepatic gluconeogenesis, visceral adiposity, hypertension, dyslipidaemia and cardiovascular disease. Many patients with hypercortisolism lack classic cushingoid features and instead present with resistant diabetes, resistant hypertension, obesity or progressive cardiometabolic disease. Emerging evidence suggests that abnormal cortisol suppression following a 1‐mg overnight dexamethasone suppression test (DST) occurs more frequently in patients with difficult‐to‐control T2D and resistant hypertension than previously appreciated. Current evidence supports a targeted case‐finding approach rather than universal screening. Patients most likely to benefit from evaluation include those with persistent hyperglycaemia despite intensive therapy, severe insulin resistance, resistant hypertension, adrenal incidentalomas or physical findings suggestive of cortisol excess. The overnight 1‐mg DST remains the preferred initial screening test because it is practical, inexpensive and widely available. Interpretation is supported by a confirmatory dexamethasone level ≥ 140 ng/dL and requires careful consideration of medication interactions, obesity, psychiatric disease, alcohol use, sleep disorders and assay variability.Conclusions and RelevanceHypercortisolism likely contributes to metabolic dysfunction in a subset of patients with T2D, particularly those with resistant cardiometabolic disease. Recognition of high‐risk phenotypes and appropriate use of the DST may improve identification of patients with potentially treatable cortisol excess. Additional prospective studies are needed to clarify optimal screening strategies and determine whether earlier diagnosis and treatment improve long‐term cardiometabolic outcomes. Introduction Hypercortisolism encompasses a spectrum of disorders characterised by excessive glucocorticoid exposure, ranging from overt endogenous Cushing syndrome to milder forms of autonomous cortisol secretion now commonly referred to as mild autonomous cortisol secretion (MACS) [1, 2]. Historically, clinically significant hypercortisolism was considered rare and largely confined to patients with classic cushingoid features such as proximal muscle weakness, facial plethora, easy bruising, skin fragility and violaceous striae [3, 4]. However, growing evidence suggests that milder forms of cortisol excess are more common than previously recognised and may contribute meaningfully to cardiometabolic disease, particularly in patients with Type 2 diabetes (T2D), obesity, resistant hypertension and adrenal incidentalomas [2, 5, 6]. The terminology surrounding hypercortisolism has evolved considerably over the past decade. The term ‘subclinical Cushing syndrome’ has largely been replaced by MACS, reflecting recognition that cortisol excess exists on a biologic continuum rather than as a binary disorder. MACS is generally defined by inadequate suppression of serum cortisol following a 1‐mg overnight dexamethasone suppression test (DST), most commonly using a post‐DST cortisol threshold greater than 1.8 μg/dL (50 nmol/L), in patients without overt catabolic manifestations of classic Cushing syndrome [7]. Even mild degrees of autonomous cortisol secretion may exert clinically important metabolic and cardiovascular effects over time [8]. Cortisol plays a central role in glucose metabolism and energy homeostasis. Chronic cortisol excess promotes hepatic gluconeogenesis, impairs peripheral insulin sensitivity, increases visceral adiposity and contributes to dyslipidaemia and hypertension. These pathophysiologic effects closely mirror the abnormalities commonly observed in T2D and metabolic syndrome, supporting the biologic plausibility that occult hypercortisolism may contribute to poor metabolic control in selected patients [1]. Importantly, many patients with MACS lack classic cushingoid features and instead present with common metabolic conditions encountered routinely in primary care and endocrinology practice [8]. Multiple studies have demonstrated increased rates of hypertension, T2D, obesity, atrial fibrillation, osteoporosis and cardiovascular disease amongst patients with MACS [9]. This phenotypic overlap likely contributes to under recognition and delayed diagnosis. Amongst patients with T2D, hypercortisolism may be particularly relevant in those with difficult‐to‐control hyperglycaemia despite intensive therapy, severe insulin resistance, resistant hypertension or unexplained progressive metabolic deterioration. Emerging evidence suggests that autonomous cortisol secretion may represent a potential therapeutic target to explore in a subset of patients with treatment‐resistant metabolic disease [9, 10]. Despite increasing awareness of MACS, uncertainty remains regarding whom to screen and how best to interpret biochemical testing. The overnight 1‐mg DST remains the cornerstone screening test because of its relative simplicity, accessibility and sensitivity for detecting impaired hypothalamic–pituitary–adrenal axis suppression [3, 4]. However, interpretation may be complicated by obesity, psychiatric disease, sleep disorders, medication interactions, alcohol use and assay variability [4, 11, 12, 13]. This review summarises current understanding of hypercortisolism in patients with T2D, with a focus on epidemiology, clinical risk factors and practical use of the DST in routine clinical practice. Defining Hypercortisolism Hypercortisolism refers to chronic glucocorticoid excess resulting from endogenous cortisol overproduction or exogenous glucocorticoid exposure. Contemporary endocrinology recognises hypercortisolism as a spectrum ranging from overt endogenous Cushing syndrome to milder forms of autonomous cortisol secretion. Overt endogenous Cushing syndrome is rare, with an estimated annual incidence of approximately 1.8–3.2 cases per million persons [14]. Most cases are adrenocorticotropic hormone (ACTH)‐dependent and caused by pituitary corticotroph adenomas, referred to as Cushing disease. Patients typically present with progressive central obesity, proximal muscle weakness, facial plethora, skin fragility, easy bruising, violaceous striae, hypertension and impaired glucose metabolism [4]. In contrast, MACS is characterised by biochemical evidence of autonomous cortisol secretion without overt cushingoid appearance. MACS is most commonly identified in patients with adrenal incidentalomas and is typically diagnosed by abnormal suppression following a 1‐mg overnight DST [7]. Although patients with MACS often lack classic physical findings, even mild cortisol excess appears associated with increased rates of hypertension, T2D, obesity, dyslipidaemia, atrial fibrillation, osteoporosis and cardiovascular disease [9]. Distinguishing autonomous cortisol secretion from functional or physiologic hypercortisolism is important because several common conditions can activate the hypothalamic–pituitary–adrenal axis and produce biochemical abnormalities resembling endogenous hypercortisolism [15]. Obesity, depression, chronic stress, alcohol use disorder, sleep disruption and poorly controlled diabetes may impair cortisol suppression despite the absence of true autonomous cortisol production [11]. Careful clinical assessment and confirmatory testing are therefore essential when interpreting abnormal screening results. Epidemiology: How Common Is Hypercortisolism in T2D? Historically, endogenous hypercortisolism was considered an uncommon cause of diabetes because overt Cushing syndrome itself is rare. Early screening studies in unselected diabetes populations generally reported low prevalence rates, reinforcing the perception that routine screening for hypercortisolism in T2D was impractical and low yield. A 2016 systematic review and meta‐analysis of 14 studies encompassing 2827 T2D patients found a pooled prevalence of hypercortisolism of 3.4% and confirmed Cushing syndrome of only 1.4% [16]. Over the past two decades, however, increasing attention has focused on milder forms of cortisol excess that may present primarily with cardiometabolic abnormalities rather than classic cushingoid features [2, 17]. More recent observational studies suggest that abnormal cortisol suppression following DST occurs more frequently in selected T2D populations than previously appreciated, particularly amongst patients with resistant diabetes, obesity, resistant hypertension or adrenal incidentalomas [16, 18, 19]. Reported prevalence estimates vary substantially across studies because of differences in patient selection, biochemical thresholds, assay methodology and diagnostic definitions. Studies focused exclusively on overt Cushing syndrome generally report very low prevalence rates, whereas investigations incorporating MACS identify substantially larger numbers of patients with autonomous cortisol secretion. A narrative review found the prevalence of confirmed Cushing syndrome in T2D to be variable, ranging from 0.6% to 9.3%, with a DST false‐positive rate ranging from 3.7% to 21% [20]. Several studies have demonstrated increased rates of abnormal DST results amongst patients with poorly controlled T2D, especially those requiring multiple antihyperglycaemic agents or high‐dose insulin therapy. Similarly, patients with resistant hypertension appear to have increased prevalence of autonomous cortisol secretion compared with the general population. The CATALYST trial has contributed substantially to contemporary understanding of hypercortisolism in difficult‐to‐control metabolic disease. This multicentre study evaluated adults with poorly controlled T2D using systematic biochemical screening protocols including the overnight DST. The study demonstrated that abnormal cortisol suppression suggestive of hypercortisolism occurred more frequently than historically appreciated in patients with resistant metabolic disease. Specifically, amongst 1057 adults with difficult‐to‐control T2D, 23.8% (95% CI 21.3–26.5) had a post‐DST cortisol > 1.8 μg/dL, using a definition that also required a confirmatory serum dexamethasone ≥ 140 ng/dL to prove adequate drug exposure. 34.7% of those with hypercortisolism had adrenal imaging abnormalities. Importantly, many affected patients lacked overt cushingoid appearance, supporting the concept that hypercortisolism may frequently present as resistant diabetes or hypertension rather than classic endocrine disease [18]. An important caveat with these data from the CATALYST trial is that they report the prevalence amongst people with difficult‐to‐treat T2D and not the general T2D population. Although the DST was performed rigorously, the study did no second‐line confirmatory testing. Additionally, the trial was sponsored by Corcept Therapeutics Inc., the manufacturer of mifepristone. Differences in screening methodology also contribute significantly to variability in prevalence estimates. Lower post‐DST cortisol thresholds improve sensitivity for detecting MACS but increase false‐positive rates, particularly in patients with obesity, psychiatric disease or physiologic stress [11]. Assay variability and differences in cortisol measurement techniques further complicate interpretation [13]. Taken together, current evidence suggests that overt Cushing syndrome remains rare amongst patients with T2D, but milder forms of autonomous cortisol secretion and structural adrenal abnormalities may be substantially more common in selected high‐risk populations than previously believed. Recognition of these high‐risk phenotypes has shifted contemporary screening strategies toward targeted case‐finding rather than reliance on classic physical features alone. Which Patients With T2D Should Be Screened? Current endocrine guidelines do not recommend universal screening for hypercortisolism in all patients with T2D because obesity, hypertension and diabetes are highly prevalent and non‐specific conditions. Instead, most experts advocate a targeted case‐finding approach focused on patients with clinical characteristics associated with increased likelihood of autonomous cortisol secretion. Poor Glycaemic Control Despite Intensive Therapy Persistent hyperglycaemia despite intensive diabetes management is one of the most clinically relevant indicators of possible hypercortisolism. Cortisol excess directly antagonises insulin action through stimulation of hepatic gluconeogenesis, impairment of peripheral glucose uptake and promotion of visceral adiposity. Consequently, patients with autonomous cortisol secretion often exhibit severe insulin resistance and progressive deterioration in glycaemic control [1]. Patients requiring multiple antihyperglycaemic agents, escalating insulin doses or unusually high insulin requirements may therefore represent a higher‐yield population for targeted screening, particularly when glycaemic deterioration appears disproportionate to the patient's degree of obesity. Resistant Hypertension Hypertension is amongst the most common manifestations of endogenous hypercortisolism and occurs in most patients with overt Cushing syndrome. Resistant hypertension appears to be highly prevalent even amongst individuals with mild hypercortisolism. In one study of 423 patients with resistant hypertension, 26.5% had an abnormal DST, and 8.0% subsequently had positive confirmatory late‐night salivary cortisol testing. Notably, none of these patients exhibited clinical features of overt Cushing syndrome [21]. Excess cortisol promotes hypertension through increased mineralocorticoid receptor activation, endothelial dysfunction, enhanced vascular reactivity and activation of the renin–angiotensin–aldosterone system [17]. Patients with T2D and resistant hypertension appear to have increased prevalence of autonomous cortisol secretion, particularly when accompanied by obesity, hypokalaemia or progressive insulin resistance [18]. The coexistence of resistant hypertension and poorly controlled T2D should therefore heighten clinical suspicion for hypercortisolism. Adrenal Incidentalomas Adrenal incidentalomas represent one of the most important clinical settings in which MACS is identified. Current estimates suggest that approximately 20%–50% of patients with adrenal incidentalomas exhibit some degree of autonomous cortisol secretion depending on diagnostic criteria used [2, 22]. Because cortisol‐producing adrenal adenomas may not produce overt cushingoid features, current guidelines recommend biochemical evaluation for cortisol autonomy in most patients with incidentally discovered adrenal masses [7]. In patients with T2D, the coexistence of an adrenal incidentaloma substantially increases the likelihood of MACS [23]. Physical Findings Suggestive of Cortisol Excess Although many patients with MACS lack classic cushingoid appearance, several physical findings remain highly suggestive of clinically significant hypercortisolism and should prompt evaluation. These include proximal muscle weakness, easy bruising, facial plethora, skin fragility and wide violaceous striae. Progressive central obesity, rapid metabolic deterioration, unexplained osteoporosis and recurrent cardiometabolic complications may also raise suspicion, particularly when disease severity appears disproportionate to conventional risk factors [20]. Selective Case‐Finding Approach An important challenge in screening for hypercortisolism is balancing diagnostic yield against false‐positive results and healthcare costs. Obesity, psychiatric illnesses, alcohol use, sleep disruption and chronic illness can all impair cortisol suppression despite the absence of autonomous cortisol secretion [4, 11, 12]. At present, a selective case‐finding strategy appears most consistent with available evidence and current guideline recommendations. Patients with resistant diabetes, resistant hypertension, adrenal incidentalomas, suggestive physical findings or progressive cardiometabolic disease appear most likely to benefit from further evaluation (see Figure 1). Proposed clinical algorithm for identifying patients with T2D who may warrant screening. The DST The overnight 1‐mg DST is amongst the most widely used and accepted screening tests for endogenous hypercortisolism in clinical practice [24]. Because it is inexpensive, accessible and relatively easy to perform, the DST is particularly useful for evaluating high‐risk patients with T2D, resistant hypertension or adrenal incidentalomas [20]. Physiologic Basis Under normal physiologic conditions, cortisol secretion is regulated through negative feedback within the hypothalamic–pituitary–adrenal axis [25]. Dexamethasone is a potent synthetic glucocorticoid that suppresses ACTH secretion. In individuals with normal hypothalamic–pituitary–adrenal axis function, dexamethasone administration suppresses morning serum cortisol concentrations. Patients with autonomous cortisol secretion exhibit impaired suppression because cortisol production becomes partially or fully independent of normal feedback regulation [3, 23]. How to Perform the Overnight 1‐mg DST Patients are instructed to take 1 mg of dexamethasone orally between 11:00 PM and midnight, followed by measurement of serum cortisol and comeasurement of dexamethasone (which should be ≥ 140 ng/dL to ensure adequate dexamethasone levels were achieved) the following morning, generally between 8:00 and 9:00 AM [3]. Clear patient instructions are essential to minimise inaccurate results. Medication reconciliation is particularly important because several commonly prescribed drugs alter dexamethasone metabolism or cortisol measurement. The overnight DST has become the preferred initial screening test in many patients because it has high sensitivity and is simpler than 24‐h urinary free cortisol suppression testing. Repeated late‐night salivary cortisol sampling has been traditionally used as a confirmatory ‘rule‐out’ test due to published data attesting to its high specificity [3]. However, emerging evidence suggests that this very specificity may miss clinically significant adrenal function abnormalities [18]. Interpreting Results In most contemporary guidelines, a post‐DST serum cortisol concentration less than 1.8 μg/dL (50 nmol/L) is considered normal and effectively excludes clinically significant autonomous cortisol secretion [3, 11]. The diagnostic performance of this threshold depends in part on the cortisol assay used, and clinicians should be aware that assay‐specific biases may influence classification of results near the cutoff value [13]. Interpretation should always occur within clinical context because mild abnormalities are relatively common in patients with obesity, psychiatric disease, alcohol use disorder, sleep disorders and physiologic stress. Common Confounders and Pitfalls Several physiologic and pharmacologic factors can interfere with DST interpretation. Drugs that induce cytochrome P450 3A4 activity, including phenytoin, carbamazepine, phenobarbital and rifampin, accelerate dexamethasone metabolism and may produce false‐positive results because inadequate dexamethasone exposure fails to suppress cortisol secretion appropriately. Oral oestrogen therapy increases cortisol‐binding globulin (CBG) concentrations and may elevate measured total serum cortisol despite normal free cortisol suppression, potentially leading to false‐positive DST results. Current Endocrine Society guidelines recommend discontinuing oral oestrogen therapy for approximately 6 weeks before testing whenever clinically feasible. When oestrogen discontinuation is not practical, alternative screening tests such as late‐night salivary cortisol or 24‐h urinary free cortisol may be preferred because they are not affected by changes in CBG concentrations [3, 11]. As mentioned, certain populations (those with obesity, depression, alcohol use disorder, obstructive sleep apnoea, chronic stress, etc.) may also impair cortisol suppression in the absence of autonomous cortisol secretion. Misclassification of DST results may occur because of physiologic confounders, medication effects and assay‐related variability. Importantly, assay bias can result in either false‐positive or false‐negative classifications, particularly when cortisol concentrations are near the diagnostic threshold. Consequently, borderline or mildly abnormal results often warrant repeat testing, confirmatory evaluation or assessment using an alternative biochemical method [13]. What to Do After an Abnormal DST Management following an abnormal DST depends on the degree of cortisol elevation, clinical suspicion and associated comorbidities. Mildly abnormal or borderline results often warrant repeat DST testing to confirm reproducibility and exclude transient physiologic hypercortisolism. Additional evaluation may include late‐night salivary cortisol testing, 24‐h urinary free cortisol measurement, plasma ACTH determination or repeat DST using confirmatory protocols. Referral to endocrinology is appropriate for patients with persistently abnormal DST results, overt clinical features of hypercortisolism, adrenal incidentalomas or unexplained progressive metabolic disease. Imaging should not be used for initial screening. Rather, it should follow abnormal biochemical testing due to the relatively high frequency of adrenal and pituitary incidentalomas in the general population and may lead to diagnostic confusion if interpreted in isolation. Alternative and Complementary Diagnostic Tests Although the overnight DST is the most used screening tool for hypercortisolism, additional biochemical tests are often necessary to confirm cortisol excess or clarify equivocal findings. Late‐night salivary cortisol testing evaluates loss of the normal circadian cortisol rhythm and is particularly useful for detecting overt Cushing syndrome. However, performance may be less reliable in patients with MACS, shift work, sleep disruption, psychiatric disease or poorly controlled diabetes [3, 7]. Measurement of 24‐h urinary free cortisol reflects integrated cortisol secretion over an entire day and remains an important confirmatory test for hypercortisolism. This test is most useful in patients with overt cortisol excess but may be normal in patients with MACS [3, 7]. Plasma ACTH measurement helps distinguish ACTH‐independent cortisol excess caused by adrenal disease from ACTH‐dependent causes such as pituitary Cushing disease or ectopic ACTH secretion. Likewise, elevated DHEA‐sulphate can help to identify ACTH‐dependent disease [4, 12]. Because no single biochemical test is perfectly sensitive or specific, multiple complementary tests are often required to confirm autonomous cortisol secretion and reduce the risk of false‐positive diagnosis. Clinical Implications and Ongoing Controversies Recognition of hypercortisolism in patients with T2D has important clinical implications because cortisol excess contributes directly to insulin resistance, hypertension, visceral adiposity and cardiovascular disease. Even MACS has been associated with adverse cardiometabolic outcomes. Recognition of autonomous cortisol secretion may help explain unexpectedly severe or progressive insulin resistance in some patients with T2D. In the CATALYST study (mifepristone use) treatment phase [26], HbA1c showed a placebo‐adjusted reduction of −1.32% (95% CI −1.81 to −0.83; p < 0.001) [26]. The CHIRACIC study, in a population of unilateral adrenal incidentaloma, showed adrenalectomy allowed 46% versus 15% of MACS patients to de‐escalate antihypertensives while maintaining BP control (p = 0.0038) [27]. Evidence for amelioration of other cardiometabolic endpoints is observational and of lower‐certainty [9]. One of the most clinically important implications of diagnosis is identification of a potentially important contributor to resistant metabolic disease. Patients with persistent hyperglycaemia, resistant hypertension or progressive cardiometabolic deterioration despite intensive therapy may have occult cortisol excess driving treatment resistance. Despite growing recognition of MACS, important controversies remain regarding whom to screen, how to interpret mild biochemical abnormalities and whether intervention consistently improves long‐term outcomes. Current guidelines favour targeted case‐finding rather than universal screening because obesity, hypertension and T2D are highly prevalent and nonspecific conditions. However, studies such as the CATALYST trial suggest that autonomous cortisol secretion may be more common than previously appreciated amongst patients with treatment‐resistant diabetes. The optimal cortisol threshold following DST also remains debated. Lower thresholds improve sensitivity for detecting MACS but reduce specificity, particularly in patients with obesity, psychiatric disease or physiologic stress. Another major unanswered question is whether all patients with MACS experience clinically meaningful harm from cortisol excess or benefit from intervention. Although observational studies consistently demonstrate associations between MACS and cardiometabolic disease, prospective outcome data remain limited. Additional studies are needed to determine whether earlier recognition and treatment of hypercortisolism improve long‐term glycaemic control, cardiovascular outcomes, quality of life and mortality in high‐risk T2D populations. Conclusions Hypercortisolism represents an increasingly recognised but underdiagnosed contributor to metabolic dysfunction in patients with T2D. Although overt Cushing syndrome remains rare, milder forms of autonomous cortisol secretion appear substantially more common in selected high‐risk populations, particularly amongst patients with resistant diabetes, resistant hypertension, adrenal incidentalomas and progressive cardiometabolic disease. Recognition of high‐risk phenotypes is essential because many affected patients lack classic cushingoid features and instead present with common metabolic abnormalities encountered routinely in primary care and endocrinology practice. The overnight 1‐mg DST remains the cornerstone screening tool because it is practical, inexpensive and widely accessible. However, interpretation requires careful consideration of medication effects, physiologic hypercortisolism, assay variability and clinical context. Importantly, identifying hypercortisolism may reveal a potentially treatable contributor to poor glycaemic control, resistant hypertension and increased cardiovascular risk. As understanding of MACS continues to evolve, greater awareness amongst non‐endocrinologists may support more individualised and mechanism‐based approaches to management of resistant cardiometabolic disease. Funding The authors have nothing to report. Conflicts of Interest Both authors were employees of Headlands Research AMCR Institute which received research grants from Corcept. However, neither has received remuneration directly from Corcept.